疫苗ETF（159643）涨超1.8%，流感活跃期或催化相关需求

Group 1 - The flu season in China may arrive earlier this year, with a higher number of infections expected due to a different circulating strain, primarily H3N2, compared to last year's H1N1 strain, leading to lower immunity in the population [1] - The treatment options for influenza include symptomatic treatment, antiviral therapy, and traditional Chinese medicine, with antiviral drugs such as neuraminidase inhibitors, RNA polymerase inhibitors, and hemagglutinin inhibitors being highlighted [1] - There is a recommendation to pay attention to the market for antiviral drugs, respiratory disease medications, and flu vaccines [1] Group 2 - The vaccine ETF (159643) tracks the vaccine biotechnology index (980015), which selects listed companies involved in vaccine research, production, biotechnology, and life sciences tools and services to reflect the overall performance of the bioproducts and life sciences sector [1] - The index components focus on innovative drug development and disease prevention, showcasing the technological development trends and investment value in the bioscience industry [1]